Skip to main content
REPL logo

REPL · Replimune Group, Inc.

Track REPL — free
$19.04 -0.19 (-0.99%)
Market Cap
$1.82B
Shares
94.80M
Volume · Nov 20 460.01K Avg daily vol (3M) 2.52M

Price & Indicators

 

Key stats

Close
$19.23
Thu 19 Nov
Open
$19.89
Thu 19 Nov
Average volume, 30 days
2.9M
shares a session
Short interest
24.6M
26.0% of shares · 8.3 days to cover
Day range
$19.15$20.48
Open $19.89 Close $19.23
52-week closing range
$1.70$23.28
Close $19.23 17.4% under the high
Short volume, last session
50%
Last earnings
Oct 28, 2026
Latest filing
10-Q · Oct 28
Price history
Jan 2020 to Nov 2026

Up next

Mar 17, 2028 Est · unconfirmed · in 69 wks

Latest documents

2026
Nov 6
Quarterly report 10-Q/A Ended Sep 30
Executives disclose insider trading arrangements

Replimune Group, Inc. disclosed Rule 10b5-1 trading arrangements entered into during the quarter ended September 30, 2026, covering 488,119 shares for Philip Astley-Sparke, 99,665 shares for Sushil Patel and 160,372 shares for Konstantinos Xynos.

5 source passages
Replimune Group, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-Q/A (this “Amendment”) to its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2026, which was originally filed with the Securities and Exchange Commission (the “SEC”) on October 28, 2026 (the “Original Filing”). This Amendment is being filed to revise Part II “Item 5. Other Information” to add certain Rule 10b5-1 trading arrangements entered into by Philip Astley-Sparke, Executive Chair of the Company, Sushil Patel, Chief Executive Officer of the Company, and Konstantinos Xynos, Chief Medical Officer of the Company, during the quarter ended September 30, 2026, which were inadvertently omitted from the disclosure included in the Original Filing. Philip Astley-Sparke,<br>Executive Chair | 08/21/2026^(2)^ | | 488,119 | 03/15/2028 Sushil Patel,<br>Chief Executive Officer and Director | 08/21/2026^(2)^ | | 99,665 | 08/20/2027 Konstantinos Xynos,<br>Chief Medical Officer | 08/20/2026^(2)^ | | 160,372 | 08/30/2027 Open the document at this passage
Oct 28
Earnings call
Tudrakev Launch Shows Early Prescriptions; No Product Revenue Yet

Replimune reported no product revenue in the fiscal second quarter, as first commercial shipments occurred in early October. Net loss for the quarter was $57.1 million, and cash ended the quarter at $307.8 million. Over 15 institutions have written one or more Tudrakev prescriptions, and about 20 accounts have placed it on formulary.

5 source passages
We did not record product revenue in the quarter as first commercial shipments occurred in early October. Net loss for the quarter was $57.1 million, compared to a net loss of $69.8 million in the fiscal first quarter. We ended the quarter with $307.8 million in cash and cash equivalents. As of Friday, over 15 institutions have written one or more Tudor Kev prescriptions, a strong start in less than 20 business dates. About 20 accounts have swiftly placed Tudrakev on formulary. Open the document at this passage
Oct 28
Quarterly report 10-Q FY2027 Q2, ended Sep 30
FDA grants accelerated approval to TUDRIQEV for advanced melanoma

Replimune Group announced FDA accelerated approval of TUDRIQEV with nivolumab for unresectable advanced cutaneous melanoma after anti-PD-1 progression, with commercial launch in early October 2026. Net loss narrowed to $57.1 million for the three months ended September 30, 2026, from $83.1 million a year earlier, partly reflecting an April 2026 restructuring. Cash and cash equivalents were $307.8 million as of September 30, 2026.

Net loss $57.12M Diluted EPS -$0.54
Read from the MD&A section
5 source passages
On August 6, 2026, we announced the FDA granted accelerated approval to TUDRIQEV (vusolimogene oderparepvec-wtpg), previously referred to as RP1, in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma who experienced disease progression on an anti-PD-1 antibody-based regimen. Since becoming commercially available in early October 2026, about 20 melanoma institutions have placed TUDRIQEV on formulary Our net losses were $57.1 million and $83.1 million for the three months ended September 30, 2026 and 2025 The reduced costs for the three and six months ended September 30, 2026 are, in part, a result of the Company restructuring that was announced in April 2026. We expect that our cash and cash equivalents of $307.8 million as of September 30, 2026 will be sufficient to fund our operations and capital expenditure requirements for greater than twelve months Open the document at this passage
Oct 28
Current report 8-K
TUDRIQEV Commercially Available; Fiscal Q2 Net Loss $57.1 Million

Replimune said TUDRIQEV became commercially available in the United States with nivolumab for advanced melanoma, with first delivered to patients on October 6th. Fiscal second quarter net loss was $57.1 million, compared with $83.1 million a year earlier.

Financial results
3 source passages
TUDRIQEV is now commercially available in the United States for use in combination with nivolumab for the treatment of adults with advanced melanoma. TUDRIQEV first delivered to patients for advanced melanoma on October 6th Net loss was $57.1 million for the fiscal second quarter ended September 30, 2026 and $83.1 million for the fiscal second quarter ended September 30, 2025. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$271.03M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-13.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$183.69M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+14.4%
Year over year · more shares
Price change (1Y)
+113.9%
Trailing year
Short interest
26.0%
Latest settlement · 8.3 days to cover
View all 125 metrics

AI Brief

Q2 FY27 earnings call · Oct 28, 2026
Q2 FY27

TL;DR. TUDRIQEV’s early launch showed more than 70% engagement with the initial 200 priority accounts, prescriptions from more than 15 institutions, broad payer coverage, and continued enrollment of IGNYTE-3 and REVEAL. Net loss improved year over year, cash and cash equivalents were $307.8 million with funding expected to last greater than 12 months, but fiscal Q2 recorded no product revenue, the company is not providing revenue guidance, and SG&A increased sequentially for launch investments.

Bullish
  • + The commercial team is nearly fully staffed and ready to execute the launch.
Bearish
  • − No product revenue was recorded in fiscal Q2 2027 because first commercial shipments occurred in early October.
  • − The company is not providing revenue guidance, and revenue from a patient may be recognized over more than one quarter.
  • − SG&A expense increased from the prior quarter because of commercial launch investments.
  • − TUDRIQEV’s accelerated approval and continued commercialization may depend on confirming clinical benefit.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +87%
above
Price vs 50-day avg +26%
above
RSI (14) 55
neutral
MACD trend Negative
52-week position 81%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +60%
trailing
6-month return +121%
trailing
YTD return +98%
this year
Relative strength +127%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $15 › 200d $10 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +47 funds added
Insider flow Distributing
Net -$2.3M over 90 days · 100% sells
Short interest Rising
25.96% of shares out · ▲ +6.2% MoM · 8.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
212 holders — near 3-yr high, broad support
Squeeze score 83
high risk · 0–100
Fundamentals
Weak
EPS growth −10%
Y/Y
Free cash flow $-282.6M
Balance sheet $100.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 188%
annualized · 1-yr
Max drawdown −84%
past year
ATR 6.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+87% Bullish
Price vs 50-day avg
+26% Bullish
RSI (14)
55 Neutral
MACD trend
Negative Bearish
52-week position
81% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $15 › 200d $10 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +47 funds added
Insider flow Distributing
Net -$2.3M over 90 days · 100% sells
Short interest Rising
25.96% of shares out · ▲ +6.2% MoM · 8.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
212 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $19 · 81% Range high $23
vs 200-day avg +87% vs 50-day avg +26%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
REPL
Replimune Group, Inc.
this stock
$1.82B +97.8% — — 26.0%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
212
% held
111.8%
Net QoQ
+10.6M sh
Top holder
BAKER BROS. ADVISORS LP
Held Float
View
Held by Funds
Fund positions
152
View
Short & Settlement
Short Interest Rising
Shares short
24.6M
Days to cover
8.3d
Change
+1.4M sh
View
Short Volume
Short vol %
50%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
561
Value
$9.8K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
36.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$2.3M
Buyers / Sellers
0 / 6
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-313.9M
EPS diluted
$-3.38
View
Filings
SEC Filings
Latest
10-Q/A
Filed
Nov 6, 2026
This year
25

Replimune Group, Inc. disclosed Rule 10b5-1 trading arrangements entered into during the quarter ended September 30, 2026, covering 488,119 shares for Philip Astley-Sparke, 99,665 shares for Sushil Patel and 160,372 shares for Konstantinos Xynos.

View
Proposed Sales
Value
$693.5K
Shares
34.5K
Filed
Nov 17, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 28, 2026
View
Investor Relations
Latest news
Replimune Reports Fiscal Second Q…
Published
Oct 28, 2026
View

Performance

5D 20D 120D MTD YTD
REPL -12.5% +60.4% +121.3% +9.2% +97.8%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -7.1% +66.7% +126.9% +14.5% +92.9%
Key facts CIK 1737953 CUSIP 76029N106 13F (30d) 228 filings 200 filers Visit website Investor relations